Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 8/20 | 0.57 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | TACR2 | P21452 | 4/20 | 0.55 |
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | CCKBR | P32239 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31634547 | 0.89 | CAPN1 (0.57) | CXCL8DPP3CAPN1CTSBTACR1 | |
| SCHEMBL31433280 | 0.87 | CXCL8 (0.56) | CXCL8DPP3TACR1 | |
| SCHEMBL31433172 | 0.87 | CAPN1 (0.57) | CXCL8DPP3CAPN1CTSB | |
| SCHEMBL31433368 | 0.85 | REN (0.52) | CXCL8CAPN1CTSB | |
| SCHEMBL30450633 | 0.82 | DPP3 (0.57) | CXCL8DPP3 | |
| SCHEMBL29973278 | 0.81 | TACR2 (0.66) | CXCL8DPP3CAPN1CTSBTACR2 | |
| SCHEMBL29461598 | 0.81 | DPP3 (0.56) | CXCL8DPP3 | |
| SCHEMBL26426326 | 0.80 | CTSL (0.65) | CXCL8 | |
| SCHEMBL30432327 | 0.80 | DPP3 (0.55) | CXCL8DPP3CCKBR | |
| SCHEMBL29974089 | 0.80 | DPP3 (0.66) | DPP3CAPN1CTSBTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | CXCL8 3338/4885DPP3 882/4885CAPN1 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.